Therapure Biopharma to divest CDMO business for $290m

19:00 EDT 4 Sep 2017 | Pharmaceutical Technology

A joint venture (JV) between 3SBio and CPE Funds has entered an asset purchase agreement to purchase Canadian biologics manufacturer Therapure Biopharma’s contract development and manufacturing (CDMO) business, Therapure Biomanufacturing, for $290m.

Original Article: Therapure Biopharma to divest CDMO business for $290m


More From BioPortfolio on "Therapure Biopharma to divest CDMO business for $290m"

Quick Search

Relevant Topics

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...